Abeona Therapeutics Announces $8.5 Million Equity Financing With Current Institutional Investors and Directors
July 28, 2015 09:03 ET
|
Abeona Therapeutics Inc
NEW YORK, NY--(Marketwired - July 28, 2015) - Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for...
Abeona Therapeutics Provides Update on SDF(TM) (Salt Diafiltration) Plasma Fractionation Products
July 07, 2015 09:07 ET
|
Abeona Therapeutics, Inc.
NEW YORK, NY--(Marketwired - July 07, 2015) - Abeona Therapeutics, Inc. (NASDAQ: ABEO)Confirms SDF™ technology platform fractions provide significantly enhanced yields of PTB-101 SDF Alpha™...
Abeona Therapeutics Raises Additional $4.6 Million Through Warrant Exercises in Q2 15
July 01, 2015 09:06 ET
|
Abeona Therapeutics
NEW YORK, NY--(Marketwired - July 01, 2015) - Abeona Therapeutics, Inc. (NASDAQ: ABEO)Financings of approximately $40 million completed to advance rare disease product developmentAbeona Therapeutics...
Abeona Therapeutics Set to Join Russell Global, Russell 3000(R) and Russell MicroCap(R) Indexes
June 22, 2015 07:03 ET
|
Abeona Therapeutics
NEW YORK, NY--(Marketwired - June 22, 2015) - Abeona Therapeutics begins trading today under ticker symbol ABEOCompany to ring NASDAQ closing bell today at 4:00 pm ETAbeona Therapeutics, Inc. (NASDAQ:...
PlasmaTech Biopharmaceuticals Announces Name Change to Abeona Therapeutics to Reflect Broader Rare Disease Commitment
June 19, 2015 08:03 ET
|
PlasmaTech Biopharmaceuticals
NEW YORK, NY--(Marketwired - June 19, 2015) - Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare...
PlasmaTech Biopharmaceuticals to Present at the 2015 BIO International Convention
June 17, 2015 07:03 ET
|
PlasmaTech Biopharmaceuticals
DALLAS, TX and NEW YORK, NY--(Marketwired - June 17, 2015) - PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and...
PlasmaTech Biopharmaceuticals Expands Rare Disease Pipeline With License Agreement for Gene Therapy in Fanconi Anemia & CRISPR/Cas9-Based Technology Platform for Rare Blood Disorders
June 15, 2015 07:03 ET
|
PlasmaTech Biopharmaceuticals
NEW YORK, NY and CLEVELAND, OH--(Marketwired - June 15, 2015) - PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI)CRISPR-Cas9 Gene-Editing System Demonstrated Promising Efficacy in Repairing the FANCC...
PlasmaTech Biopharmaceuticals Announces License Agreement for AAV Gene Therapy to Treat Patients With Juvenile Batten Disease
June 08, 2015 07:03 ET
|
PlasmaTech Biopharmaceuticals
NEW YORK, NY--(Marketwired - June 08, 2015) - PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI)Company Adds Third AAV Gene Program to Expand Pipeline and Become a leader in Gene Therapies for Severe...
PlasmaTech Biopharmaceuticals to Present at the 2015 Jefferies Healthcare Conference
June 01, 2015 10:37 ET
|
PlasmaTech Biopharmaceuticals
DALLAS, TX and NEW YORK, NY--(Marketwired - June 01, 2015) - PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and...
PlasmaTech Biopharmaceuticals to Present at the 2015 LD Micro Invitational Conference
May 29, 2015 13:28 ET
|
PlasmaTech Biopharmaceuticals
DALLAS, TX and NEW YORK, NY--(Marketwired - May 29, 2015) - PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and...